Hsiao D. Lieu - 04 Nov 2022 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC

Role
SVP, Chief Medical Officer
Signature
David Woodhouse, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
04 Nov 2022
Net transactions value
$0
Form type
4
Filing time
08 Nov 2022, 20:07:04 UTC
Previous filing
04 Mar 2022
Next filing
06 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGM Stock Option (Right to Buy) Award $0 +150,000 $0.000000 150,000 04 Nov 2022 Common Stock 150,000 $5.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 50% of the shares subject to the option vest on each of November 4, 2023 November 4, 2024.